UBS Group Cuts Acumen Pharmaceuticals (NASDAQ:ABOS) Price Target to $4.00
Acumen Pharmaceuticals (NASDAQ:ABOS – Free Report) had its price objective trimmed by UBS Group from $6.00 to $4.00 in a research report report published on Friday morning,Benzinga reports. The firm currently has a buy rating on the stock. Separately, HC Wainwright dropped their target price on Acumen Pharmaceuticals from $15.00 to $11.00 and set a […]
Acumen Pharmaceuticals (NASDAQ:ABOS – Free Report) had its price objective trimmed by UBS Group from $6.00 to $4.00 in a research report report published on Friday morning,Benzinga reports. The firm currently has a buy rating on the stock. Separately, HC Wainwright dropped their target price on Acumen Pharmaceuticals from $15.00 to $11.00 and set a […]
